levemir insulin detemir prefilled pen 3ml 300IU per prefilled pen

Description

Indication & Scope

Levemir® is a prescription long-acting basal insulin analogue indicated to improve glycemic control in adults and children 2 years of age and older with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus requiring basal insulin therapy. It provides stable basal insulin coverage with a reduced risk of nocturnal hypoglycemia compared with NPH insulin. It is not indicated for the treatment of diabetic ketoacidosis.

Mechanism: Insulin detemir is a recombinant long-acting insulin analogue that binds to insulin receptors, promoting glucose uptake and suppressing hepatic glucose production. Reversible albumin binding prolongs its duration of action.
Drug class: Long-acting basal insulin analogue.
Clinical use: Basal insulin therapy for type 1 diabetes and type 2 diabetes requiring improved glycemic control.

Specification

Generic Name	Insulin Detemir Injection
Brand Name	Levemir®
Ingredient	Insulin Detemir
Dosage Form	Injection
Package	3 mL /prefilled FlexPen (300 IU, 100 IU/mL)
Conditions Treated	Type 1 diabetes mellitus; Type 2 diabetes mellitus requiring basal insulin
Taboos	Hypoglycemia; hypersensitivity to insulin detemir or any formulation component
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Unopened: refrigerate at 2–8°C. Do not freeze. In-use pens may be stored below 30°C for up to 6 weeks, protected from heat and light.
Manufacturer	Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	S20217003
Approval Date	May 14, 2021
Shelf Life	24 months

How to use ?

Recommended Dose: Individualized according to blood glucose levels. Adults with type 2 diabetes typically start with 10 units or 0.1–0.2 units/kg once daily. Patients with type 1 diabetes require individualized basal insulin as part of a basal-bolus regimen.

Time: Inject once or twice daily at the same time each day.

Instructions for use: Administer by subcutaneous injection only into the abdomen, thigh, or upper arm. Rotate injection sites. Do not dilute, mix with other insulins, or use in an insulin pump or by intravenous injection.

Interaction: Oral antidiabetic agents, GLP-1 receptor agonists, ACE inhibitors, salicylates, and alcohol may increase hypoglycemia risk. Corticosteroids, thyroid hormones, diuretics, and sympathomimetics may increase insulin requirements.

Side effects: Common adverse reactions include hypoglycemia, injection-site reactions, lipodystrophy, edema, weight gain, allergic reactions, and transient visual changes.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support